MediumEndocrinologyType 2 diabetes with cardiovascular diseaseau-racpau-amc
A 64-year-old man with type 2 diabetes for 12 years, established coronary artery disease and an estimated glomerular filtration rate (eGFR) of 55 mL/min/1.73 m² is on metformin and a sulfonylurea. His HbA1c is 8.1% (65 mmol/mol). According to current Australian diabetes and cardiovascular guidelines, which additional class of glucose-lowering medication has the strongest evidence for cardiovascular and renal benefit in this setting?